Outcome of patients less than 55 years of age with high-risk acute leukemia who did not have an human leukocyte antigen-identical related donor: a long-term study of 97 consecutive patients

• Published in: Leukemia & lymphoma Vol. 46; no. 6; pp. 841 - 849
• Main Authors: Cornillon, Jérôme, Fawaz, Abir, Depil, Stéphane, Dufosse, Françoise, Duhamel, Alain, Bauters, Francis, Fenaux, Pierre, Jouet, Jean-Pierre, Yakoub-Agha, Ibrahim
• Format: Journal Article
• Language: English
• Published: United States Informa UK Ltd 01-06-2005; Taylor & Francis
• Subjects: Adolescent; Adult; allogeneic stem cell transplantation; autologous tem cell transplantation; Child; Child, Preschool; Female; high-risk acute leukemia; Histocompatibility Testing; HLA Antigens - chemistry; Humans; Infant; Leukemia, Myeloid, Acute - mortality; Leukemia, Myeloid, Acute - therapy; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality; Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy; Stem Cell Transplantation - methods; Transplantation, Autologous - methods; Treatment Outcome; unrelated donor search
• ISSN: 1042-8194; 1029-2403
• DOI: 10.1080/10428190500080090

Between January 1993 and December 2000, an unrelated donor search (UDS) was initiated for 97 consecutive patients [46 acute lymphoblastic leukemia (ALL) and 51 acute myeloid leukemia (AML)]. Leukemia was considered to be of poor prognosis in cases of refractory disease (n=70), unfavourable karyotype (n=22) or miscellaneous (n=5). All patients had previously received various chemotherapies and 9 had undergone an autologous stem cell transplantation (SCT). The median age at UDS initiation was 25 (range 2.7-55) years. The median time to identify a suitable living donor or cord blood (CB) was 60 days. Eventually, 33 patients received unrelated allo-SCT (including 9 CB), 12 auto-SCT, 39 chemotherapy and 13 palliative treatment. At a median of 54 months, 18 patients were alive, including 15 in remission. The 4-year overall survival rates were 32%, 37%, 15% and 0% for allo-SCT, auto-SCT, chemotherapy or palliative treatment, respectively. Patients who received either allo- or auto-SCT had better survival than those who did not (P<0.0001). For ALL, only allo-SCT significantly improved survival (P<0.007). Finally, patients who received allo-SCT died less often of relapse than patients who did not (P<0.0001). Unrelated allo-SCT gives a substantial long-term survival and cure in patients with high-risk acute leukemia. For patients who achieve remission and for whom UDS fails, auto-SCT may prove to be a good approach. For patients who fail to enter into remission, intensive salvage chemotherapy has a very limited effect.